Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

19177 items
12:00 AM, Mar 01, 1993  |  BioCentury | Product Development

Rethinking Phase II in Antril's wake

Rethinking Phase II in Antril's wake By Karen Bernstein Editor-in-ChiefThe dramatic difference between the results of Synergen Inc.'s Phase II and Phase III Antril trials, while pointing up the difficulty of conducting sepsis trials, also...
12:00 AM, Mar 01, 1993  |  BioCentury | Finance

Analyst picks & changes

Agouron Pharmaceuticals Inc. (AGPH) Biomatrix Inc. (BIOX) Cambridge NeuroScience Inc. (CNSI) Chiron Corp. (CHIR) Corvas International Inc. (CVAS) Enzon Inc . (ENZN) Genelabs Technologies Inc. (GNLB) Genetic Therapy Inc. (GTII) Genetics Institute Inc. (GENIZ) Genentech Inc. ...
12:00 AM, Mar 01, 1993  |  BioCentury | Politics, Policy & Law

Healy resigns, blaming abortion politics for ouster

Healy resigns, blaming abortion politics for ouster WASHINGTON - Bernadine Healy announced Friday that she has been forced out of her position as director of the National Institutes of Health because of her role...
12:00 AM, Mar 01, 1993  |  BioCentury | Finance

Analyst picks & changes

Amgen Inc. Amgen Inc.'s announcement last week of sluggish U.S. Neupogen G-CSF sales for the quarter to date triggered a spate of analyst reappraisals on AMGN, just three weeks after lower-than-expected fourth quarter earnings sent...
12:00 AM, Mar 01, 1993  |  BioCentury | Politics, Policy & Law

Wyden explains his position

Wyden explains his position Rep. Ron Wyden has announced plans to introduce legislation significantly modifying the relationships between federal laboratories, research institutions and the private companies involved in commercializing innovations. Wyden chaired hearings two weeks...
12:00 AM, Mar 01, 1993  |  BioCentury | Politics, Policy & Law

Ask for Clinton's vote

Ask for Clinton's vote "Regulatory policy can have a significant impact on the rate of technology development in energy, biotechnology, pharmaceuticals, telecommunications and many other areas." "Regulatory...
12:00 AM, Mar 01, 1993  |  BioCentury | Finance

BioBundle, IPOs grind to a halt

BioBundle, IPOs grind to a halt By Karen Bernstein Editor-in-ChiefFinancial fallout from the disappointing Phase III data from Synergen Inc.'s Antril sepsis drug was not long in coming, leading to the postponement last week of...
12:00 AM, Feb 22, 1993  |  BioCentury | Politics, Policy & Law

Technology incentives launched

WASHINGTON - Amid the uproar over the President's blast at drug prices, the Congress and the White House last week called for the implementation of targeted capital gains legislation supported by the biotech industry. The legislation...
12:00 AM, Feb 22, 1993  |  BioCentury | Politics, Policy & Law

NIH prepares to unveil its position on pricing

WASHINGTON - NIH Director Bernadine Healy this week is scheduled to describe the agency's "current thinking" on whether it should play a role in imposing federal price restraints on drugs that are co-developed with private...
12:00 AM, Feb 22, 1993  |  BioCentury | Politics, Policy & Law

Get up off the mat

Get up off the mat On Inauguration Week, we expressed concern on this page that the biotechnology industry would be at risk if it allowed itself to be defined by outside forces, whether from the...

Pages